Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib

BACKGROUND: Tirabrutinib, a second-generation inhibitor of Bruton’s tyrosine kinase, was approved in March 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (r/r PCNSL) based on phase I/II studies in Japan. We previously reported the overall response rate and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Yoshiki, Narita, Yoshitaka, Nagane, Motoo, Mishima, Kazuhiko, Terui, Yasuhito, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Aoi, Arata, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517093/
https://www.ncbi.nlm.nih.gov/pubmed/37744697
http://dx.doi.org/10.1093/noajnl/vdad109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517093/
https://www.ncbi.nlm.nih.gov/pubmed/37744697
http://dx.doi.org/10.1093/noajnl/vdad109

Ejemplares similares